IL13 and Alzheimer disease: Tralokinumab, a fully human monoclonal antibody binding IL-13, acts by preventing the binding of IL-13 to both IL-13Rα1 and IL-13Rα2, resulting in the blockage of its signal transduction, showed to be a safe as and effective treatment option, even in monotherapy in adult AD patients (52, 58, 62, 63).